AUPH Aurinia Pharmaceuticals Inc

15
+6.61  (+79%)
Previous Close 8.39
Open 16.7
Price To Book 11.45
Market Cap 1,414,890,000
Shares 94,285,008
Volume 41,591,566
Short Ratio
Av. Daily Volume 1,647,676
Stock charts supplied by TradingView

NewsSee all news

  1. Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

    - Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified

  2. Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

    University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion

  3. Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

    - Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential

  4. Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing

  5. Aurinia Announces Updates to the Board of Directors

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions,

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2/3 data due 2H 2020.
Voclosporin
Dry eye syndrome
Phase 2 interim data due 2020.
Voclosporin
Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)
48-week data from open-label AURION study presented March 27, 2017 - primary endpoint met.
Voclosporin - AURION trial
Lupus
Phase 3 trial met primary endpoint - December 4, 2019.
Voclosporin - AURORA
Lupus
Phase 2 trial enrollment has commenced - noted June 25, 2018.
Voclosporin - AURORA 2
Lupus

Latest News

  1. Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

    - Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care - - Statistically significant results demonstrated in all pre-specified

  2. Hepion Pharmaceuticals Announces Canadian Research Team's Academic Appointments

    University of Alberta's Faculty of Pharmacy and Pharmaceutical Sciences Appoints Hepion's Drs. Foster, Mayo, Ure and Trepanier as Adjunct Professors EDISON, NJ / ACCESSWIRE / December 3, 2019 / Hepion

  3. Aurinia to Present Preclinical Voclosporin Data at 2020 Keystone Symposia Conference

    - Voclosporin demonstrated fewer adverse effects on beta cell function as compared to tacrolimus in preclinical model of diabetes - - Data supports differentiation of voclosporin versus legacy CNIs and potential

  4. Aurinia Reports Third Quarter 2019 Financial Results and Recent Operational Highlights

    - Conference call and webcast to be hosted today at 4:30pm EDT – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing

  5. Aurinia Announces Updates to the Board of Directors

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused on advancing voclosporin across multiple inflammatory and autoimmune conditions,

  6. Aurinia Completes Voclosporin Drug-Drug Interaction Study Demonstrating No Clinically Significant Interaction With Mycophenolate Mofetil

    - Data support differentiation of voclosporin as a potential best-in-class CNI - Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company focused

  7. Aurinia Pharmaceuticals to Release Third Quarter 2019 Financial Results on November 14, 2019

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that it will release its third quarter 2019 financial results on Thursday, November 14, 2019, after the market closes. Aurinia's

  8. Aurinia Announces Initiation of Patient Dosing in Phase 2/3 AUDREY™ Clinical Trial for Dry Eye Syndrome

    - Voclosporin ophthalmic solution (VOS) AUDREY trial results anticipated in the second half of 2020 – Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical

  9. Aurinia Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will participate in a fireside chat at the 2019 Cantor Global

  10. Aurinia Establishes At-the-Market Facility

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) ("Aurinia" or the "Company"), a late- stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced that it has

  11. Aurinia Pharmaceuticals to Present at the 21st Annual H.C. Wainwright Global Investment Conference

    Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH, TSX:AUP) (the "Company") today announced that Peter Greenleaf, President and Chief Executive Officer of Aurinia, will present a corporate overview at the 21st Annual H.C.